Artificial intelligence (AI) is revolutionizing countless fields, and healthcare is no exception. As the world faces multiple crises, international cooperation in healthcare AI has the potential to support the global economy, promote peace, and push the boundaries of globalization.
Technology to grow AI unicorns
Richard Yang, Sinovation Ventures Partner
Richard Yang, Sinovation Ventures
Among the many companies that have contributed to this cause, one company is making headlines. Sinovation Ventures, Asia’s leading AI venture capitalist firm founded by Dr. Kai-Fu Lee. One of his key figures is Richard Yang, a partner in his Sinovation Disrupt Fund, his $500 million technology fund focused on growth investments. With his 18 years of experience in technology entrepreneurship and investment, Yang manages a diverse portfolio of companies in the health and productivity sectors around the world. Yang’s impressive work extends to building and supporting numerous unicorns, including the likes of Mega Robo.
I had the chance to meet Daniel Huang, the founder and CEO of Megarobo, at an MIT Technology Review event called EmTech in Suzhou in 2020. The test automation startup has grown to over 1,000 employees in less than two years and has attracted investment from Goldman Sachs. Unicorn rating.
After all, this is one of many unicorn companies that Sinovation has invested in and achieved unicorn status. But Mega Robo is a very good example of well-timed investment and strategic support from investors. Similar trends in Japan have prompted many Chinese manufacturers to launch large-scale automation efforts and rapidly develop robotic solutions that are as good or better than those familiar in the West. Many of these solutions are highly customizable and can be created on demand. For example, Agile Robots helped build a robot for Neuralink to create brain implants. China’s laboratory automation sector was growing even before the pandemic, with startups building drones that pack and move goods in warehouses, deliver food to offices and mix drinks in bars. Some have started working on the development of inspection robots. Automate multiple processes in biology and chemistry labs. However, some start-ups have entered the space from the ground up, combining expertise in automation with life science expertise.
In 2020 there were two distinct leaders, Megarobo and X-Imaging (just to be clear, X-Imaging helped build my fully robotic target-finding lab. ). Sinovation made the initial company investment decision, helped establish many collaborations, and facilitated the introduction of several other investors. During the pandemic, demand for lab automation increased and the company turned into a unicorn. Now they’re investing heavily in his AI, his services, his providers, his business. Timing the market, identifying leaders, providing sufficient capital, maximizing AI, and supporting collaboration are nothing new, but have worked time and time again in Sinovation.
Importance of being global
The company will set up an AI and Quantum Computing Research Center in Abu Dhabi, UAE in 2022 and has partnered with Saudi Arabia’s Aramco. The Middle East, also known as Middle-earth, where East meets West, is transforming into a peaceful and prosperous region. It serves as a fertile ground for technological progress and is an ideal place to set up a base and explore investment opportunities. During my last visit to the UAE, I was able to meet Richard Yang in person and ask him some questions.
As part of our conversation with Mr. Yang, I would love to hear his views on healthcare AI, his experiences in the UAE and China, and his views on the future amid a volatile geopolitical climate. rice field.
“I used to visit the UAE on business.From a business perspective, there is great interest and experience in AI here,” Yang explained. “This time I came on vacation to understand the culture a bit more.I am amazed at the liveliness and vibrancy of this place.The people here are very optimistic and have a very bright outlook for the future. But this is rare.”
This optimism resonates with the potential for international cooperation in AI healthcare. AI will shape the economy and promote peace as the AI revolution in medicine continues. International players like Yang are understanding global cultures, bridging gaps, making connections, and shaping the future of healthcare AI.
Global collaboration in healthcare AI serves as a beacon of hope as we navigate this difficult time. It provides innovative solutions to health crises, supports economic recovery and paves the way for a more interconnected and peaceful world. The future of AI in healthcare looks promising, and leaders like Yang continue to push boundaries and inspire optimism.
Alex: What do you see as the future of AI in healthcare in China, the US, and MENA countries? What do you think are the big differences between regions?
Richard Yang: AI in healthcare will become very ubiquitous. In any country, an AI healthcare system will address two major problems he said: a shrinking workforce and a rapidly aging population.
And although the UAE has a young workforce, much of it can be unlocked with the power of AI to augment the workforce. It’s a powerful infrastructure technology that everyone can use.
In AI healthcare, the business aspects are different, but the products and features can be globally similar. For example, I invested in a company that specializes in smart wheelchairs. Many robots will help us in the near future.
And my hope is that the global technology, business, and governance communities can collaborate on this subject of AI. We cannot accept a future in which billions of people are deprived of care because of an aging population.
Alex: What about from a funding perspective?
Richard Yang: Companies may invest in multifaceted solutions for diagnostics, preventative care, maintenance, and more. I think this is an investment that can have a big impact on longevity.
Money will follow wherever the market is. I identify markets where healthcare and productivity are interconnected, both addressing the challenges of an aging population. From this perspective, we are in the early days of investing in both. According to Statisia, 10% of the world’s population is over the age of 65, with Europe leading with 19% of her. Imagine 10 years from now…
We’ve talked a lot about China and the many challenges you’re trying to address with your investments. Please tell us about the characteristics of investment in China.
First and foremost, I can say without hesitation that I am deeply concerned about China and its challenges. I truly want to support this effort through my work and investments, and by supporting the entrepreneurial community with advice, connections and resources. We also want the most talented and innovative international companies to come to China and bring new ideas, talents and even culture. That’s why I really enjoyed my trip to UAE where I met many promising companies and entrepreneurs. Also, it gives me great pleasure to see the companies I have invested in expand into the UAE and other her MENA countries. It’s great to see these companies succeed and contribute to the global healthcare ecosystem.
In my view, we are witnessing a golden generation of Chinese entrepreneurs. They were born after him in 1985 and grew up with a world-class education, an open mindset and a global outlook. They have created successful businesses and many value social responsibility. Since China opened up its economy in the early 1990s, this third wave of talent has started to shine.
I became an entrepreneur by chance. My co-founders and I intuitively wanted to do something different when we started the company. When I look at young founders these days, I am often amazed at how great people can become with good intentions and conditions. Again, this is also what I have seen in the UAE over the last few days.
Alex: What do you think of the current disconnect between China and the US? Should we expect a major impact on healthcare? And how are you and your portfolio companies preparing for this?
Richard Yang: Well, I can only talk about the Chinese side?
For the time being, the impact is likely to reach foreign-affiliated companies. These companies have recently entered or started operations in China and must ensure compliance with local laws and regulations.
When the healthcare industry and capital separate, many things will have to be coordinated on both sides. New technology cannot be shared. Business opportunities are separated. And most unfortunately, we could lose many lives that could have been saved.
I know enough to talk about potential challenges on the Chinese side. For example, long-cycle, capital-intensive businesses such as drug discovery may struggle due to lack of local funding. VCs and PEs in the healthcare sector could see a significant reduction in terms of public exits.
My advice to investee companies is to prepare for the worst and pursue the best. We have reached an agreement that they will:
- Aiming to be No. 1 in the sector
- achieve large-scale commercialization
- Maintain a cash runway for 24 months
- Be truly global.
And I’m doing everything in my power to help these Chinese entrepreneurs weather the storm and hopefully go to the UAE.
follow me twitter Or LinkedIn. check out You can find my website and other works here.
